These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 21890092)

  • 1. Mode of death and hospitalization from the Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial and comparison of clinical events committee adjudicated versus investigator reported outcomes.
    O'Connor CM; Fiuzat M; Lindenfeld J; Miller A; Lombardi C; Carson P; Shaw LK; Wang LJ; Connolly P; Mills R; Yancy C; Mahaffey K
    Am J Cardiol; 2011 Nov; 108(10):1449-57. PubMed ID: 21890092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial.
    Yancy CW; Krum H; Massie BM; Silver MA; Stevenson LW; Cheng M; Kim SS; Evans R;
    Circ Heart Fail; 2008 May; 1(1):9-16. PubMed ID: 19808265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential applications of outpatient nesiritide infusions in patients with advanced heart failure and concomitant renal insufficiency (from the Follow-Up Serial Infusions of Nesiritide [FUSION I] trial).
    Yancy CW; Singh A
    Am J Cardiol; 2006 Jul; 98(2):226-9. PubMed ID: 16828598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (β-Blocker Evaluation of Survival Trial [BEST]).
    Carson P; Fiuzat M; O'Connor C; Anand I; Plehn J; Lindenfeld JA; Silver M; White M; Miller A; Davis G; Robertson AD; Bristow M; Gottlieb S
    Am Heart J; 2010 Oct; 160(4):649-54. PubMed ID: 20934558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: study rationale and design.
    Yancy CW; Krum H; Massie BM; Silver MA; Stevenson LW; Cheng M; Kim SS; Evans R;
    Am Heart J; 2007 Apr; 153(4):478-84. PubMed ID: 17383282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acutely decompensated heart failure in a county emergency department: a double-blind randomized controlled comparison of nesiritide versus placebo treatment.
    Miller AH; Nazeer S; Pepe P; Estes B; Gorman A; Yancy CW
    Ann Emerg Med; 2008 May; 51(5):571-8. PubMed ID: 18304693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial).
    Yancy CW; Saltzberg MT; Berkowitz RL; Bertolet B; Vijayaraghavan K; Burnham K; Oren RM; Walker K; Horton DP; Silver MA
    Am J Cardiol; 2004 Sep; 94(5):595-601. PubMed ID: 15342289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing classifications of death in the Mode Selection Trial: agreement and disagreement among site investigators and a clinical events committee.
    Petersen JL; Haque G; Hellkamp AS; Flaker GC; Mark Estes NA; Marchlinski FE; McAnulty JH; Greenspon AJ; Marinchak RA; Lee KL; Lamas GA; Mahaffey KW;
    Contemp Clin Trials; 2006 Jun; 27(3):260-8. PubMed ID: 16574497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Observation unit treatment of heart failure with nesiritide: results from the proaction trial.
    Peacock WF; Holland R; Gyarmathy R; Dunbar L; Klapholz M; Horton DP; de Lissovoy G; Emerman CL
    J Emerg Med; 2005 Oct; 29(3):243-52. PubMed ID: 16183441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure.
    Lindenfeld J; Feldman AM; Saxon L; Boehmer J; Carson P; Ghali JK; Anand I; Singh S; Steinberg JS; Jaski B; DeMarco T; Mann D; Yong P; Galle E; Ecklund F; Bristow M
    Circulation; 2007 Jan; 115(2):204-12. PubMed ID: 17190867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of serial home infusions of nesiritide for advanced heart failure.
    Chung ES; Menon SG; Daly KA; Atkinson J; Peterson T; Robertson R; Ibanez K; Kereiakes DJ
    Am J Cardiol; 2006 May; 97(9):1370-3. PubMed ID: 16635613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic nesiritide does not prevent dialysis or all-cause mortality in patients undergoing high-risk cardiac surgery.
    Ejaz AA; Martin TD; Johnson RJ; Winterstein AG; Klodell CT; Hess PJ; Ali AK; Whidden EM; Staples NL; Alexander JA; House-Fancher MA; Beaver TM
    J Thorac Cardiovasc Surg; 2009 Oct; 138(4):959-64. PubMed ID: 19660420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with B-type natriuretic peptide for chronic decompensated heart failure: insights learned from the follow-up serial infusion of nesiritide (FUSION) trial.
    Yancy CW
    Heart Fail Rev; 2004 Jul; 9(3):209-16. PubMed ID: 15809819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial.
    Wedel H; Demets D; Deedwania P; Fagerberg B; Goldstein S; Gottlieb S; Hjalmarson A; Kjekshus J; Waagstein F; Wikstrand J;
    Am Heart J; 2001 Sep; 142(3):502-11. PubMed ID: 11526365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Where patients with mild to moderate heart failure die: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
    Olshansky B; Wood F; Hellkamp AS; Poole JE; Anderson J; Johnson GW; Boineau R; Domanski MJ; Mark DB; Lee KL; Bardy GH;
    Am Heart J; 2007 Jun; 153(6):1089-94. PubMed ID: 17540216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale, design, and methods for the Transplant-Eligible MAnagement of Congestive Heart Failure (TMAC) trial: a multicenter clinical outcomes trial using nesiritide for TMAC.
    Mehra MR; McCluskey T; Barr M; Bourge RC; Jessup ML; Mancini D; Radovancevic B; Rayburn B; Taylor DO; Lilly-Hersley J; Linde P
    Am Heart J; 2007 Jun; 153(6):932-40. PubMed ID: 17540193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial.
    Anand IS; Carson P; Galle E; Song R; Boehmer J; Ghali JK; Jaski B; Lindenfeld J; O'Connor C; Steinberg JS; Leigh J; Yong P; Kosorok MR; Feldman AM; DeMets D; Bristow MR
    Circulation; 2009 Feb; 119(7):969-77. PubMed ID: 19204305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE; Lombraña A; Duarte P; Di Gennaro F
    J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF).
    Gheorghiade M; Gattis Stough W; Adams KF; Jaffe AS; Hasselblad V; O'Connor CM
    Am J Cardiol; 2005 Sep; 96(6A):18G-25G. PubMed ID: 16181819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF).
    Hernandez AF; O'Connor CM; Starling RC; Reist CJ; Armstrong PW; Dickstein K; Lorenz TJ; Gibler WB; Hasselblad V; Komajda M; Massie B; McMurray JJ; Nieminen M; Rouleau JL; Swedberg K; Califf RM
    Am Heart J; 2009 Feb; 157(2):271-7. PubMed ID: 19185633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.